Keywords: Amylin, Eli Lilly, Alkermes, Bydureon, Type 2 diabetes

Amylin and Lilly to re-file Bydureon with US FDA sooner than expected with new tQT data

Article | 11 July 2011

Print This

Amylin Pharmaceuticals (Nasdaq: AMLN), Eli Lilly (NYSE: LLY) and Alkermes (Nasdaq: ALKS) have announced results from a thorough QT (tQT) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in